Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Items 801–900 of 999
Toriyama, K., Masago, K., Shibata, N., Haneda, M., Kuwahara, T., Natsume, S., Kobayashi, S., Fujita, Y., Sasaki, E., Yamao, K., et al. (2025) · The Journal of Pathology · doi:10.1002/path.6432 · Cited by 6
Griffith, B. D., Kadiyala, P., McGue, J. J., Sun, L., Kumar, A., Espinoza, C. E., Donahue, K. L., Iyer, M. K., Speyer, C. B., Nelson, S., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0377 · Cited by 11
KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Wei, Y., Liu, M., Yen, E.-Y., Yao, J., Xun, Z., Nguyen, P. T.-M., Wang, X., Yang, Z., Yousef, A. M. G., Pan, D. N., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2024 · Cited by 7
Self-citationWhittle, M. C., & Hingorani, S. R. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000289 · Cited by 4
Aberrant activation of KRAS in mouse theca-interstitial cells results in female infertility
Sun, P., Wang, H., Liu, L., Guo, K., Li, X., Cao, Y., Ko, C. J., Lan, Z., & Lei, Z. M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.991719 · Cited by 4
“Kras expression in the ovary, theca cells, granulosa cells, interstitial cells and testes was detected by RT-PCR using the primer set (5′-aggcctgctgaaaatgactg-3′ and 5′-ccctccccagttctcatg ta-3′, Eurofins Genomics LLC) followed by digestion of amplified PCR products with Hind III (Promega Corp) as described (Aguirre et…”
MethodPancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
Esmail, A., Badheeb, M. A., & Abdelrahim, M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110887 · Cited by 4
Fu, J., Ling, J., Li, C.-F., Tsai, C.-L., Yin, W., Hou, J., Chen, P., Cao, Y., Kang, Y., Sun, Y.-C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47242-3 · Cited by 6
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
Possible Involvement of Pancreatic Fatty Infiltration in Pancreatic Carcinogenesis
Hori, M., Mutoh, M., Imai, T., Nakagama, H., & Takahashi, M. (2016) · JOP, journal of the pancreas · Cited by 5
Yazawa, K., Nakamura, F., Masukawa, D., Sato, S., Hiroshima, Y., Yabushita, Y., Mori, R., Matsuyama, R., Kato, I., Taniguchi, H., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100746 · Cited by 7
“The development of genetically engineered mouse models with PDAC, such as Pdx1-Cre; LSL-Kras [10], Pdx1-Cre; LSL-Kras; Ink4a/Arf [11], and Pdx1-Cre; LSLKras; LSL-p53 [7], has facilitated our understanding of the molecular mechanisms of pancreatic neoplasia [10,12].”
BackgroundWang, H., Moniruzzaman, R., Li, L., Ji, B., Liu, Y., Zuo, X., Abbasgholizadeh, R., Zhao, J., Liu, G., Wang, R. L., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163873 · Cited by 4
The small heat shock protein αA-crystallin negatively regulates pancreatic tumorigenesis
Liu, J., Luo, Z., Zhang, L., Wang, L., Nie, Q., Wang, Z.-F., Huang, Z., Hu, X., Gong, L., Arrigo, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11668 · Cited by 4
Gene expression analysis of pancreatic cystic neoplasm in SV40Tag transgenic mice model
Feng, J. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i15.2218 · Cited by 4
“However, genetic engineering has been shown to effectively generate mice with germline oncogenic lesions similar to human pancreatic adenocarcinomas [ 1 ]”
BackgroundThe Utility of Transgenic Mouse Models for Cancer Prevention Research
Hursting, S. D., Lashinger, L. M., Brown, P. H., & Perkins, S. N. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_18 · Cited by 4
Metaplastic Metamorphoses in the Mammalian Pancreas
Konieczny, S. F., & Leach, S. D. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.10.061 · Cited by 4
Quelle, D. E., Nteeba, J., & Darbro, B. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30060-8 · Cited by 6
McAndrews, K. M., Mahadevan, K. K., Li, B., Sockwell, A. M., Morse, S. J., Kelly, P. J., Patel, S. I., Kirtley, M. L., Diaz, B. A. M., Lyu, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.29.635543 · Cited by 4
Ihle, N. T. (2012) · Digital Commons-TMC (Texas Medical Center) · Cited by 6
A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma
Zhuo, M., Li, Y., Zhang, Y., Yang, C. R., Zou, D., Xu, W., Han, J., Wang, S., Deng, H., Pan, X., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.021 · Cited by 6
Technologies for Identification and Validation of Cancer Biomarkers
Javed, A., Sher, H., Huma, Z., & Khan, I. N. (2022) · Springer eBooks · doi:10.1007/978-981-16-5759-7_2 · Cited by 3
Koe, J. C., Zhong, Y. C., Pashaoskooie, K., Kaczorowski, G. J., García, M. L., & Parker, S. J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110525 · Cited by 3
Proteomic insights into early pancreatic ductal adenocarcinoma biology and screening
Huang, Y., Sun, C., Gao, X., Zhai, S., Wang, G., & Zhang, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03317-1 · Cited by 5
“Pancreatic invasive neoplasia can take years to develop, offering a window for early detection, especially in high-risk groups [11, 12].”
Mechanisms of Hippo pathway in the pancreatic cancer
Xie, R., & Chen, R. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000041 · Cited by 4
Quadruplex nucleic acids in KRAS targeted-cancer therapy
Xodo, L. E. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.04.004 · Cited by 3
Dairo, G., Ilesanmi, A., Balogun, T. A., Ward, M. N., Soendergaard, M., & Determan, J. J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2191133 · Cited by 4
“…of certain tumor suppressor genes such as tumor protein 53 (p53), Smad4, cyclin-dependent kinase inhibitor 2 A (CDKN2A), and phosphatase and ten-sin homolog deleted on chromosome 10 (PTEN) is known to initiate cancer progression amongst others (Aguirre et al., 2003; Hingorani et al., 2003, 2005).”
BackgroundConcerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics
Layeghi‐Ghalehsoukhteh, S., Choudhuri, S. P., Ocal, O., Zolghadri, Y., Pashkov, V., Niederstrasser, H., Posner, B. A., Kantheti, H. S., Azevedo‐Pouly, A. C. P., Huang, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77373-8 · Cited by 3
Models of Pancreatic Cancer: Understanding Disease Progression
Melstrom, L. G., & Grippo, P. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_9 · Cited by 5
TGF-β as Tumor Suppressor: Lessons from Mouse Models
Valcourt, U., Vincent, D. F., & Bartholin, L. (2013) · Springer eBooks · doi:10.1007/978-4-431-54409-8_6 · Cited by 3
Genetically Engineered Mouse Models in Preclinical Anti-Cancer Drug Development
Sergio, Y., & Melinda, G. (2011) · InTech eBooks · doi:10.5772/30666 · Cited by 9
Bioinformatics and Systems Biology of Cancers
Omenn, G. S. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385071-3.00007-1 · Cited by 4
Induction of Histiocytic Sarcoma in Mouse Skeletal Muscle
Liu, J., Hettmer, S., Milsom, M. D., Hofmann, I., Hua, F., Miller, C. M., Bronson, R. T., & Wagers, A. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044044 · Cited by 3
“Moreover, constitutively activated Kras(G12D) combined with p16/p19 deficiency induces aggressive cancers in a number of non-hematopoietic tissues and organs in mice [17–24].”
BackgroundA New Preclinical Paradigm for Pancreas Cancer
Hingorani, S. R. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1160-5_4 · Cited by 3
Aberrant Signaling Pathways in Pancreatic Cancer
Norris, A. M., & Korc, M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00324-7 · Cited by 5
From Inception to Invasion: Modeling Pathways to Pancreatic Cancer
Hingorani, S. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_10 · Cited by 5
Williams, T. M., Estrada, A., Chatterjee, M., Yang, L., Morgan, M. A., & Robinson, C. A. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.975 · Cited by 4
Fanale, D., Madonia, G., Galvano, A., Peeters, M., ten Tije, A. J., Iovanna, J., & Russo, A. D. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_40 · Cited by 3
Adenocarcinoma of the Pancreas
Fanta, P. T., & Lowy, A. M. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch87 · Cited by 3
Generation and characterization of a transgenic mouse model for pancreatic cancer
Sun, Q. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i17.2785 · Cited by 3
Lineage-Specific Transcription Factors in Carcinogenesis
David, C. J., & Vanharanta, S. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060524-105603 · Cited by 3
Models and Mechanisms of High-Fat Diet (HFD) Promotion of Pancreatic Cancer
Chang, H.-H., Eibl, G., & Rozengurt, E. (2015) · Energy balance and cancer · doi:10.1007/978-3-319-16733-6_10 · Cited by 2
Pancreatic Stress and Regeneration
di Magliano, M. P. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.024 · Cited by 3
Significance of Tumor Microenvironment for Regulating Pancreatic Cancer
Ijichi, H. (2023) · Cancers · doi:10.3390/cancers15092482 · Cited by 3
Zhang, Y., Zheng, F., Wang, F., Liu, X., Xiang, C., Fu, S., Shen, K., & Liu, G. (2023) · Biomedicines · doi:10.3390/biomedicines11112962 · Cited by 2
Rac1 GTPase Regulates the βTrCP-Mediated Proteolysis of YAP Independently of the LATS1/2 Kinases
Palanivel, C., Somers, T. N., Gabler, B. M., Chen, Y., Zeng, Y., Cox, J. L., Seshacharyulu, P., Dong, J., Yan, Y., Batra, S. K., et al. (2024) · Cancers · doi:10.3390/cancers16213605 · Cited by 4
“In these models, the pancreas-specific expression of oncogenic KRAS is combined with the loss of a tumor suppressor to drive the formation of pancreatic intraepithelial neoplasia (PanIN) lesions and their progression to PC [7–11].”
BackgroundNalbantoğlu, S., & Amri, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817532-3.00006-2 · Cited by 2
Shining the spotlight on shed kras in pancreatic cancer
Sempere, L. F., & Korc, M. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.3.5582 · Cited by 2
Lin, Y., Yu, J. H., Lin, L., Cao, Y., Zhang, Y., Chen, S.-F., & Zheng, C.-Q. (2014) · Gene · doi:10.1016/j.gene.2014.01.081 · Cited by 2
RetractedBascom, J. L., & Kenny, P. A. (2005) · Breast Cancer Research · doi:10.1186/bcr1030 · Cited by 2
“Using a series of floxed alleles on a PDX-Cre background he delineated a successive requirement for K-Ras activation, Ink4A/Arf loss and p53 loss in pancreatic cancer progression [15]”
BackgroundDietary Fatty Acids and Cancer
Glauert, H. P. (2007) · Food science and technology · doi:10.1201/9781420006902.ch45 · Cited by 2
Molecular Pathology of Precursor Lesions of Pancreatic Cancer
Feldmann, G., & Maitra, A. (2009) · Springer eBooks · doi:10.1007/978-0-387-77498-5_5 · Cited by 3
Animal Modeling of Pancreatitis-to-Cancer Progression
Martinelli, P., & Real, F. X. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_66 · Cited by 2
Sikdar, N., Dey, S., & Banerjee, S. (2022) · Springer eBooks · doi:10.1007/978-981-15-9411-3_157 · Cited by 2
Apoptosis Signaling Pathways in Pancreatic Cancer Pathogenesis
McConkey, D. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-77498-5_14 · Cited by 2
A continuous approach of modeling tumorigenesis and axons regulation for the pancreatic cancer
Chaaya, M.-J., Chauvet, S., Hubert, F., Mann, F., Mezache, M., & Pudlo, P. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111967 · Cited by 3
“The second component of our criterion is a penalization term to capture the correct behavior of the model according to the biological knowledge we have on the chronology of appearances of PDAC cells(see Aguirre et al., 2003) in the control group (AA).”
Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Development
O’Hagan, R. C., Wu, M., Rideout, W. M., Zhou, Y., & Heyer, J. (2007) · Humana Press eBooks · doi:10.1385/1-59259-893-5:247 · Cited by 2
Leder, A., McMenamin, J., Zhou, F., Moran, J. L., Beier, D. R., & Leder, P. (2007) · Oncogene · doi:10.1038/sj.onc.1210866 · Cited by 2
“This association between oncogenic ras and Ink4a p16/p19 inactivation has been described for tumors in both humans (Guan et al., 1999; Tannapfel et al., 2000) and mice (Linardopoulos et al., 1995; Chin et al., 1997; Lin and Lowe, 2001; Uhrbom et al., 2002; Aguirre et al., 2003).”
BackgroundNew Frontiers in Pancreatic Cancer Research
Khan, G. N., di Magliano, M. P., & Simeone, D. M. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2009.11.010 · Cited by 2
Molecular biology, models, and histopathology of chronic pancreatitis and pancreatic cancer
Mihaljević, A. L., Esposito, I., Frieß, H., & Kleeff, J. H. (2009) · European surgery. Supplement/European surgery · doi:10.1007/s10353-009-0496-3 · Cited by 2
“K-RAS activation has convincingly been established as an initiating event in PDAC development by genetically engineered mouse models expressing activating K-RAS mutations (like K-RAS) that develop PanINs which progress to PDAC similar to humans [63] as well as by”
BackgroundBailey, J. M., Hendley, A. M., & Maitra, A. (2015) · Pancreas · doi:10.1097/mpa.0000000000000374 · Cited by 2
“Loss of the tumor suppressors Smad4 or p16 in mouse pancreatic progenitor cells with mutant Kras also promotes formation of PanIN and PDAC.(11,12) Still, mouse models showing formation of other premalignant ductal lesions such as intraductal papillary mucinous neoplasms and PDA have been described, including the model…”
BackgroundInfluentialTargeting Transforming Growth Factor-β in Metastasis: In Vitro and In Vivo Mechanisms
Reiß, M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-293-9_37 · Cited by 2
Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma
Kantheti, H. S., Hale, M. A., Choudhuri, S. P., Huang, H., Wang, X., Zolghadri, Y., Innamorati, G., Manikonda, S. P. R., Reddy, N. R., Reddy, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126619 · Cited by 1
“To identify diagnostic and prognostic protein markers for all stages of pancreatic disease, we first isolated protein from PDA tumors in the mouse models of PDA, KC and KIC [7] and used mass spectrometry (MS) to identify differentially expressed proteins [8,9].”
BackgroundMethodYan, B., Fritsche, A., Haußner, E., Inamdar, T. V., Laumen, H., Boettcher, M., Gericke, M. T., Michl, P., & Rosendahl, J. (2025) · Cancers · doi:10.3390/cancers17101676 · Cited by 1
“Other combinations, such as Rb1 loss [37] or Ink4a/Arf deletion [38] with Kras G12D , also result in aggressive tumorigenesis due to the disruption of cell cycle regulation pathways.”
Loss of Sorting Nexin 10 Accelerates KRAS-Induced Pancreatic Tumorigenesis
Khan, K., Shameem, M., Sigafoos, A. N., Kiey, L., Hagen, C. E., Ramakrishnan, G., Morse, L., Fernández-Zapico, M. E., & Battaglino, R. A. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0168 · Cited by 1
Martin, M. B., Mousavi, F., Goebel, G., Stasi, D. D., Mano, A., Glogov, A., Zhao, L., Guglielmo, G. M. D., Shooshtari, P., & Pin, C. L. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02777-2 · Cited by 2
“However, KRAS mutations alone are not suf fi cient for causing pancreatic cancer, and additional events, such as mutations in CDNK2A , SMAD4, and TP53 [4 – 7] or injury [8], are required for PDAC progression.”
Parrasia, S., Paoli, C., Varanita, T., Brillo, V., Abdel-Salam, M. A. L., Ongaro, A., Honisch, C., Angi, B., Bachmann, M., Bergamin, F., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108150 · Cited by 1
Pancreatic Cancer—Advances in the Last 50 Years
Barreto, S. G., Maitra, A., O'Reilly, E. M., Sahani, D., Zheng, R., & Yeo, C. J. (2026) · World Journal of Surgery · doi:10.1002/wjs.70309 · Cited by 2
Genetically Engineered Mouse Models of Pancreatic Ductal Adenocarcinoma
Hezel, A. F., & Bardeesy, N. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_16 · Cited by 1
“Pdx1-Cre Spectrum of PanINs and some mice develop PDAC with long latency [ 57 , 58]”
BackgroundInfluentialSelf-citationL’adénocarcinome pancréatique : une tumeur dépendante des lipoprotéines
Vasseur, S., & Guillaumond, F. (2015) · médecine/sciences · doi:10.1051/medsci/20153108009 · Cited by 1
“L’accumulation de macrophages infectés dans certains tissus pourrait être expliquée par une modification de leurs propriétés migratoires et contribuer ainsi à la dissémination du virus notamment dans des régions difficilement accessibles aux traitements [3].”
BackgroundInfluentialHedgehog Signaling Pathways in Pancreatic Cancer Pathogenesis
di Magliano, M. P., & Hebrok, M. (2009) · Springer eBooks · doi:10.1007/978-0-387-77498-5_16 · Cited by 1
Acuna, L., & Armando, J. (2013) · Cited by 1
Molecular Signaling Pathways in Pancreatic Cancer
Boland, G. M., & Thayer, S. P. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_11 · Cited by 3
Turrini, O., Cano, C. E., Legoffic, A., Delpéro, J., Dagorn, J., & Iovanna, J. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.02.046 · Cited by 1
“[14] Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al.”
BackgroundModels for pancreatic cancer: Giant steps forward, miles to go
Thomas, R. M., & Lowy, A. M. (2005) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2005.05.012 · Cited by 1
Mouse Models of Pancreatic Ductal Adenocarcinoma
Bednar, F., & di Magliano, M. P. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6549-2_7 · Cited by 1
Epigenetic Changes and Potential Targets in Pancreatic Cancer
Singh, R., Lillard, J. W., & Singh, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-24951-3_2 · Cited by 1
Mouse models of gastrointestinal cancers in drug development and research
Ahmed, I., Pappas, S. G., & Masood, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00011-8 · Cited by 1
Mouse models of pancreatic cancer: An ever-emerging arm of cancer drug discovery
Ganguly, K., Batra, S. K., & Kaur, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00010-6 · Cited by 1
Kožik, B., Krajnović, M., Kokanov, N., Jovanović-Ćupić, S., Božović, A., Todorović, L., & Mandušić, V. (2022) · Archives of Biological Sciences · doi:10.2298/abs220222011k · Cited by 1
Mutant K-Ras-Mediated Oxidative Stress in Pancreatic Cancer
Thomas, D., Sagar, S., Caffrey, T., & Radhakrishnan, P. (2022) · Springer eBooks · doi:10.1007/978-981-15-9411-3_94 · Cited by 1
Mouse Models of Pancreatic Exocrine Cancer
Pérez-Mancera, P. A. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_77 · Cited by 1
A shifting adversary: control of pancreatic cancer transcriptomic subtypes
David, C. J. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.71 · Cited by 1
Corbo, V., Mafficini, A., Amato, E., & Scarpa, A. (2012) · Springer eBooks · doi:10.1007/978-94-007-5842-1_8 · Cited by 1
Molecular biology of pancreatic ductal adenocarcinoma
Coleman, S. J., & Rhim, A. D. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000104 · Cited by 2
“In genetically engineered mouse models, loss of Ink4A and overexpression of K-RAS lead to rapid pancreatic tumor formation [23].”
Mouse Models of Pancreatic Cancer
Ostapoff, K. T., Dellinger, M. T., Awasthi, N., Brekken, R. A., & Schwarz, R. E. (2013) · Springer eBooks · doi:10.1007/978-94-007-7835-1_4 · Cited by 1
Molecular Relationships Between Chronic Pancreatitis and Cancer
Logsdon, C. D., Ji, B., & Hwang, R. F. (2009) · Springer eBooks · doi:10.1007/978-0-387-77498-5_11 · Cited by 2
Novel Therapeutic Strategies for Pancreatic Cancer
Quinn, B. A. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/t39h-kj31 · Cited by 2
Animal Modeling of Pancreatitis-to-Cancer Progression
Martinelli, P., & Real, F. X. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_66-1 · Cited by 1
Sikdar, N., Dey, S., & Banerjee, S. (2021) · Springer eBooks · doi:10.1007/978-981-15-4501-6_157-1 · Cited by 1
Zooming in on the cell biology of disease
Perera, R. M. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e21-09-0459 · Cited by 2
“In the early 2000s the development of several genetically engineered mouse models of PDA that faithfully recapitulate aspects of the human disease provided an unprecedented ability to study its spatial and temporal evolution in a living host (Aguirre et al., 2003; Hingorani et al., 2003, 2005; Bardeesy et al., 2006; G…”
BackgroundExperimental Model for Pancreatic Cancer and Its Therapeutic Implications in Clinical Research
Jayaraman, S., Ponnusamy, B., Rajagopal, P., Kumar, S. G., & Chandrasekar, K. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_39 · Cited by 1
Walcheck, M. T., Nukaya, M., Ranheim, E. A., Matkowskyj, K. A., & Ronnekleiv‐Kelly, S. M. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2202788 · Cited by 1
Darbro, B. W. (2007) · doi:10.17077/etd.2qnj4kik · Cited by 1
Mouse Models of Pancreatic Exocrine Cancer
(2012) · Springer eBooks · doi:10.1007/springerreference_72809 · Cited by 1
PANCREATIC CARCINOGENESIS AND PROGRESSION
Furukawa, T. (2008) · Pancreas · doi:10.1097/01.mpa.0000325594.46227.55 · Cited by 1
Dietary Fatty Acids and Cancer
Glauert, H. P. (2019) · The Open Nutrition Journal · doi:10.2174/1874288201913010027 · Cited by 1
Pancreatic carcinogenesis and progression
Furukawa, T. (2007) · Suizo · doi:10.2958/suizo.22.3 · Cited by 1
Pancreatic Cancer Management by Pentacyclic TriterpenesPreprint
Alqahtani, A. M. S., Kadasah, S. F., & Radwan, M. O. (2024) · Preprints.org · doi:10.20944/preprints202402.1741.v1
Ink4a Locus: Beyond Cell Cycle
Enders, G. H. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0711-0_10
Schneider, G., & Schmid, R. M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_13
The Biology of K-Ras Signaling Pathways in Pancreatic Cancer
Court, H., Philips, M. R., & Bar‐Sagi, D. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6549-2_5
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.